JP2012522007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522007A5
JP2012522007A5 JP2012502295A JP2012502295A JP2012522007A5 JP 2012522007 A5 JP2012522007 A5 JP 2012522007A5 JP 2012502295 A JP2012502295 A JP 2012502295A JP 2012502295 A JP2012502295 A JP 2012502295A JP 2012522007 A5 JP2012522007 A5 JP 2012522007A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
oxazin
oxo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502295A
Other languages
English (en)
Japanese (ja)
Other versions
JP5730281B2 (ja
JP2012522007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028878 external-priority patent/WO2010111626A2/en
Publication of JP2012522007A publication Critical patent/JP2012522007A/ja
Publication of JP2012522007A5 publication Critical patent/JP2012522007A5/ja
Application granted granted Critical
Publication of JP5730281B2 publication Critical patent/JP5730281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502295A 2009-03-27 2010-03-26 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 Active JP5730281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16413209P 2009-03-27 2009-03-27
US61/164,132 2009-03-27
PCT/US2010/028878 WO2010111626A2 (en) 2009-03-27 2010-03-26 Poly (adp-ribose) polymerase (parp) inhibitors

Publications (3)

Publication Number Publication Date
JP2012522007A JP2012522007A (ja) 2012-09-20
JP2012522007A5 true JP2012522007A5 (enExample) 2013-05-16
JP5730281B2 JP5730281B2 (ja) 2015-06-10

Family

ID=42288484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502295A Active JP5730281B2 (ja) 2009-03-27 2010-03-26 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤

Country Status (4)

Country Link
US (1) US8669249B2 (enExample)
EP (1) EP2415767B1 (enExample)
JP (1) JP5730281B2 (enExample)
WO (1) WO2010111626A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
US9227985B2 (en) 2013-03-15 2016-01-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EP2996692B1 (en) 2013-05-14 2021-06-30 Medizinische Hochschule Hannover Means and methods for treating cancer
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MY180775A (en) 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
JP6871169B2 (ja) 2015-03-02 2021-05-12 シナイ ヘルス システム 相同組換え因子
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
WO2019105915A1 (en) 2017-11-28 2019-06-06 F. Hoffmann-La Roche Ag New heterocyclic compounds
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
JP2021511364A (ja) 2018-01-29 2021-05-06 カディラ ヘルスケア リミティド 抗菌剤として有用な複素環式化合物
CN110526907B (zh) * 2018-05-23 2021-04-23 四川大学 苯并噁嗪酮类衍生物及其应用
EP3966208A4 (en) * 2019-05-10 2024-01-03 Antidote IP Holdings, LLC COMPOUNDS AND METHODS OF TREATING CANCER
HUE071067T2 (hu) * 2019-07-19 2025-07-28 Astrazeneca Ab PARP1 inhibitorok
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2022261011A1 (en) * 2021-04-22 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
WO2022223025A1 (zh) * 2021-04-23 2022-10-27 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
EP4410791A4 (en) * 2021-09-30 2025-10-22 Xizang Haisco Pharmaceutical Co Ltd BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE
US20240400586A1 (en) * 2021-09-30 2024-12-05 Haisco Pharmaceutical Group Co., Ltd. Heteroaryl derivative parp inhibitor and use thereof
JP7762306B2 (ja) * 2021-11-19 2025-10-29 康百達（四川）生物医薬科技有限公司 選択的ｐａｒｐ１阻害剤およびその用途
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
KR20250128449A (ko) * 2024-02-20 2025-08-28 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB8824343D0 (en) 1987-10-20 1988-11-23 Ici Australia Operations Herbicidal sulfonamides
EP0980362B1 (de) 1997-05-02 2006-08-16 Schering Aktiengesellschaft Substituierte heterocyclen und deren verwendung in arzneimitteln
KR20010079778A (ko) 1998-09-09 2001-08-22 이시하라 겐조 제초제로 유용한 융합-벤젠 유도체
WO2000017201A1 (en) * 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
DE10056312A1 (de) * 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
PE20060653A1 (es) * 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
US8022382B2 (en) * 2005-03-11 2011-09-20 Taiwan Semiconductor Manufacturing Company, Ltd. Phase change memory devices with reduced programming current
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
AU2008223348A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety

Similar Documents

Publication Publication Date Title
JP7148683B2 (ja) 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物
CA2793086C (en) Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
AU2005292152B2 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
JP5753194B2 (ja) 治療用化合物、及び関連する使用の方法
JP2013542937A5 (enExample)
CA2729408C (en) Triazole derivative or salt thereof
WO2013111108A1 (en) 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO1995018097A1 (en) Anthranilic acid derivative
HU230787B1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
JP2017512794A5 (enExample)
KR20130032863A (ko) 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도
JP2009531309A5 (enExample)
JP2013032343A (ja) 治療用化合物、及び関連する使用の方法
AU2008263166A1 (en) Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
NZ763263A (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
ES2539290T3 (es) Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso
AU2023317959A1 (en) Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
CN116589425A (zh) 组织蛋白酶l抑制剂
CA2879816C (en) Methanethione compounds having antiviral activity
CN103153990B (zh) 新型吡啶基苯并噁嗪衍生物、包含其的药物组合物及其用途
JP7616609B2 (ja) Ｒｎａウイルス感染症を処置する為のアリール－ｎ－アリール誘導体
KR101127725B1 (ko) 아미드 유도체
RU2821520C2 (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
HK1227751A1 (en) Therapeutic compounds and related methods of use